 ROCKVILLE, MD, Jan. 04, 2023 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President Chief Executive Officer of MacroGenics, will provide a business update on Thursday, January 12, 2023, at 9:45 am PT 12:45 pm ET. 